Experimental melanoma drug was rejected twice because the Food and Drug Administration questioned its study design.
Source link
Replimune Gets Third Try at FDA Approval After Makary Departure
Date:
Date:
Experimental melanoma drug was rejected twice because the Food and Drug Administration questioned its study design.
Source link